Euramos 1
Download
1 / 18

EURAMOS 1 - PowerPoint PPT Presentation


  • 239 Views
  • Uploaded on

EURAMOS 1. A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. Jeremy Whelan for the EURAMOS 1 Trial Management Group, 4 th November 2006. EURAMOS.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' EURAMOS 1' - roz


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Euramos 1

EURAMOS 1

A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy

Jeremy Whelan for the EURAMOS 1 Trial Management Group, 4th November 2006


Euramos
EURAMOS

  • EURAMOS is the European and American Osteosarcoma Study Group. The study was founded in 2001.

    • Children’s Oncology Group

    • Cooperative Osteosarcoma Study Group

    • European Osteosarcoma Intergroup

    • Scandinavian Sarcoma Group


Euramos1
EURAMOS

  • Established Oct 2001

  • Aim

    • to improve survival from OS

  • Objectives

    • to carry out large international randomised trials

    • to facilitate biological research

    • to seek new therapeutic approaches

    • to develop common understanding and methodologies for staging, pathology etc.


Euramos 11
EURAMOS 1

  • Co-sponsored

    • MRC in Europe

    • COG for North America

  • Co-ordinating Data Centre

    • MRC Clinical Trials Unit



Trial design1
Trial Design

  • Key registration criteria

    • High grade OS of extremity or axial skeleton

    • Resectable disease

    • Fit for treatment


Trial design2
Trial Design

  • Key randomisation criteria

    • Adequate pre-operative chemotherapy

    • Macroscopically complete resection of primary tumour

    • Complete removal of all metastases or complete removal planned and feasible

    • Histological response assessment


Trial design3
Trial Design

  • Primary Objectives

    • Addition of IE to post-op MAP chemotherapy improves EFS for poor responders

    • Addition of ifn to post-op MAP chemotherapy improves EFS for good responders


Trial design4
Trial Design

  • Secondary Objectives

    • Additional treatment improves OS, short and long term toxicity and quality of life

    • Additional treatment improves EFS in localised disease

    • Investigate biological and clinical correlated to histological response and outcome

    • International cooperation in trials

    • Examine outcome of the entire cohort of patients


Trial design additional studies
Trial Design- additional studies

  • Quality of Life

  • Biology Studies




Progress almost ready
Progress: almost ready

  • Austria

  • Finland


Progress requests to join
Progress: requests to join

  • Czech Republic

  • Ireland

  • Poland

  • Israel


Accrual
Accrual

302 Registered


Accrual1
Accrual

  • 302 Registered


Accrual2
Accrual

123 Randomised


Euramos 12
EURAMOS 1

  • Chief Investigators

    • Mark Bernstein (TMG Chair)

    • Neyssa Marina (COG)

    • Stephan Bielack (COSS)

    • Jeremy Whelan (EOI)

    • Sigbjorn Smeland (SSG)

  • Website

    • www.euramos.org